Stockscreener 앱 받기
114.66
0.95%
-1.10
시장 영업 전:
113.51
-1.15
-1.00%
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Bioanalytical Services Market Top Companies StudyPPD, Inc., - openPR.com
Should Weakness in Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
Cell and Gene Therapy Manufacturing Quality Control Market - openPR.com
Animal Model Market Is Booming Worldwide 2025-2032 | Charles River Laboratories International - openPR.com
Mice Model Market Seeking Excellent Growth | Charles River, Taconic Biosciences, The Jackson Laboratory - openPR.com
High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.
Radiopharmaceutical Preclinical CRO Market With In-Detailed - openPR.com
Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break - MSN
U.S. Formulation Development Outsourcing Market is Set - openPR.com
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development - Business Wire
Charles River Laboratories Announces Third-Quarter 2024 Results - ADVFN
1,000 monkeys in limbo, some stranded in Frederick, Maryland after shipments from Asia - KFOX
Jefferies Adjusts Price Target on Charles River Laboratories International to $100 From $169, Maintains Hold Rating - marketscreener.com
According to the Latest Report: Dermatology CRO Market - openPR.com
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - MSN
20 Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Ecotoxicology Market Detailed in New Research Report By 2032| Charles River Laboratories International - openPR.com
Baird Adjusts Price Target on Charles River Laboratories International to $118 From $101, Keeps Neutral Rating - marketscreener.com
Charles River (CRL) Receives Price Target Boost from Baird Analyst | CRL Stock News - GuruFocus
Charles River (CRL) Receives Price Target Boost from Baird Analy - GuruFocus
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? - Benzinga
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call | CRL Stock News - GuruFocus
Charles River Labs Earnings: Key Q1 2025 Results Coming May 7What to Watch - Stock Titan
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? - Yahoo
Charles River (CRL) Price Target Reduced Amid Challenges in Life Sciences Sector | CRL Stock News - GuruFocus
US Stocks Climb With Strong Performances From Real Estate And Utilities - Finimize
US Markets Climb As Sectors Shine With Solid Gains - Finimize
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
TD Cowen Adjusts Charles River Laboratories International's PT to $105 From $179, Keeps Hold Rating - MarketScreener
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN
Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback - Seeking Alpha
Charles River Faces Significant Regulatory And Macro Pressures (NYSE:CRL) - Seeking Alpha
Charles River (CRL) Faces Uncertainty with FDA's Shift from Animal Testing | CRL Stock News - GuruFocus
Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday? - Benzinga
Baird Adjusts PT on Charles River Laboratories International to $101 From $155, Keeps Neutral Rating - MarketScreener
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210 - MarketScreener
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga
Charles River (CRL) Faces Uncertainty with FDA's Shift on Animal Testing | CRL Stock News - GuruFocus
FDA's Shift in Testing Requirements Poses Challenge for Charles River (CRL) | CRL Stock News - GuruFocus
Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? - Insider Monkey
Charles River Laboratories International Inc (CRL) Stock Price D - GuruFocus
Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era - TipRanks
Charles River: Putting FVE Under Review After FDA Announces Plans to Phase Out Animal Testing - Morningstar
Charles River Laboratories (CRL) Faces Impact from FDA's Shift A - GuruFocus
Inotiv and Charles River stock tumble as FDA moves away from animal testing - Investing.com Canada
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River Labs stock tumbles as FDA shifts from animal testing - Investing.com Canada
FDA Shifts Away from Animal Testing, Charles River (CRL) Shares Could Be Impacted | CRL Stock News - GuruFocus
0.12%
자본화:
|
볼륨(24시간):